Targeting drug-resistant breast cancers using enzyme-stimulating peptides
New approach based on enzyme stimulating of peptides for targeting drug resistance breast cancers
['FUNDING_OTHER'] · UNIVERSITY OF NORTH TEXAS · NIH-10909182
This study is exploring a new treatment for triple-negative breast cancer that uses specially designed molecules to help stop the cancer cells from growing, and if successful, it could offer hope for patients who currently have limited options.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NORTH TEXAS (nih funded) |
| Locations | 1 site (DENTON, UNITED STATES) |
| Trial ID | NIH-10909182 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new treatments for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer that does not respond to standard hormonal therapies. The approach involves using specially designed peptides that interact with the Eyes Absent enzyme (EYA) to inhibit the growth of TNBC cells. By leveraging the unique enzymatic properties of EYA, the researchers aim to create nanostructures that can induce cell death specifically in TNBC cells, offering a novel therapeutic strategy. Patients may benefit from this innovative treatment if it proves effective in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with triple-negative breast cancer who have not responded to conventional treatments.
Not a fit: Patients with other types of breast cancer that respond to hormonal therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with drug-resistant breast cancers.
How similar studies have performed: While the approach of using enzymatic reactions to target cancer cells is innovative, similar strategies have shown promise in other cancer types, suggesting potential for success in this area.
Where this research is happening
DENTON, UNITED STATES
- UNIVERSITY OF NORTH TEXAS — DENTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HABIBI, NEDA — UNIVERSITY OF NORTH TEXAS
- Study coordinator: HABIBI, NEDA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.